Oramed Pharmaceuticals Net Income Over Time
| ORMP Stock | USD 3.38 0.05 1.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oramed Pharmaceuticals Performance and Oramed Pharmaceuticals Correlation. Can Pharmaceuticals industry sustain growth momentum? Does Oramed have expansion opportunities? Factors like these will boost the valuation of Oramed Pharmaceuticals. Anticipated expansion of Oramed directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Oramed Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.409 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets |
Oramed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oramed's balance sheet. Smart investors calculate Oramed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Oramed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oramed Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oramed Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Oramed Pharmaceuticals and related stocks such as Ovid Therapeutics, Context Therapeutics, and Clene Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| IMA | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (16.8 M) | (44.3 M) | (34.1 M) | (68.8 M) | (68.2 M) | (36.6 M) | (32.9 M) | (34.6 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
Oramed Pharmaceuticals and related stocks such as Ovid Therapeutics, Context Therapeutics, and Clene Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Oramed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Oramed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Oramed Pharmaceuticals | ORMP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1185 Avenue of |
| Exchange | NASDAQ Exchange |
USD 3.38
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.